TORONTO, Feb. 9 /PRNewswire-FirstCall/ - Spectral today announces its participation in the Japanese Society of Critical and Endotoxemia Meeting, February 9 - 11, 2007, in Tokyo. Dr. Paul Walker, President and CEO of Spectral is the invited key note speaker and will talk on the role of Endotoxin in several critical illnesses, as measured by the EAA(TM). Ms. Debra Foster, Director of Spectral’s Sepsis Program will be presenting clinical experience on the use of EAA(TM).
“This is a very important meeting for Spectral and its Joint Alliance Partner Toray Medical, as there will be a number of lectures presented by Japanese Clinicians, where linking the use of the EAA(TM) in patients with therapeutic interventions has led to significant benefit in patient care,” stated Dr. Paul Walker.
“In addition, we are near completion of a multi-site combined efficacy study using the EAA(TM) and Toray’s PMX column together,” stated Ms. Foster. “Toray’s PMX column is an effective therapy for Endotoxemia and the EAA(TM) is able to identify patients who are Endotoxemic and thus might benefit from the therapy, as well as guiding the use of this intervention, leading to better patient care.”
Toray Medical Co., Ltd. is a subsidiary company of Toray, a leading diversified chemicals corporate group that has been technology-focused since its foundation in 1926. The company’s operations are underpinned by technological expertise in organic synthetic chemistry, polymer chemistry, and biochemistry. These innovative technologies have yielded “advanced materials” that Toray is now exploiting to provide customers with comprehensive solutions through Fibers and Textiles, Plastics and Chemicals, IT-related Products, Carbon Fiber Composite Materials, Environment and Engineering, Life Science and Other Business divisions. In FY2005, Toray had consolidated sales of 1,427 billion yen (approx $12 billion US), and over 33,000 employees worldwide. For further information, please check www.toray.co.jp.
Spectral is a developer of innovative technologies for comprehensive disease management. Spectral provides accurate and timely information to clinicians enabling the early initiation of appropriate and targeted therapy. Current products include Spectral’s FDA approved rapid West Nile Virus (WNV) assay and its FDA approved rapid diagnostic for sepsis (EAA(TM)) as well as a range of other biological reagents. Spectral’s common shares are listed on The Toronto Stock Exchange under the symbol SDI.
Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral’s senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.
Spectral Diagnostics Inc.
CONTACT: Spectral Diagnostics Inc., Dr. Paul Walker, Chief ExecutiveOfficer, (416) 626-3233
